Alnylam Pharmaceuticals | ALNY - Ebitda



金融业
股票价格
USD
资产
USD 5.13B
现金及等价物
USD 1.71B
销售成本
USD 211.12M
流动资产
USD 4.22B
流动负债
USD 1.35B
债务
USD 1.28B
EBIT
USD 137.59M
EBITDA
USD 145.22M
员工
2.23K
EPS每股收益
USD 1.99
股本和储备
USD 1.08B
销售毛利
USD 825.01M
债务利息支出
USD 69.29M
利息收入
USD 26.63M
贷款资金
USD 2.48B
市值
USD 37.63B
净收入
USD 205.99M
营业费用
USD 898.54M
营业利润
USD 137.59M
普通股股本
USD 133.44M
PE价格收益
80.04
税前利润
USD 221.65M
销售收入
USD 1.17B
销售和管理费用
USD 282.51M
股票
USD 200.15M
贸易债权人
USD 126.63M
应收帐款人
USD 883.96M


Ebitda 更改 日
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Arrowhead Research USD 57.17M 7.03M 2025-12
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.84B 235M 2025-09
PTC Therapeutics USD -70.99M 91.62M 2025-12
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Sanofi EUR 5.66B 3.77B 2025-09
Sarepta Therapeutics USD -252.2M 84.16M 2025-12
Takeda JPY 150.25B 297.88B 2026-03
Tectonic Therapeutic USD -21.18M 365K 2025-12
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03
Xencor USD -51.05M 55.28M 2025-12